Stocks Health care CLGN
NASDAQ · Health careCollPlant Biotechnologies Ltd (CLGN)
CollPlant Biotechnologies Ltd reported revenue of $2.4M in fiscal 2025, up 360.4% from a year earlier. It posted a net loss of $11.5M. In fiscal 2025 capital spending exceeded operating cash flow by $9.4M. At December 31, 2025 it held $5.6M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 26, 2026.
What CollPlant Biotechnologies Ltd does
CollPlant Biotechnologies Ltd is registered with the SEC under industry code SIC 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). Its shares trade on NASDAQ under the ticker CLGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.4M | -$11.5M | -$0.94 | -$9.4M |
| 2024 | $515K | -$16.6M | -$1.45 | -$14.6M |
| 2023 | $11M | -$7M | -$0.62 | -$3.7M |
| 2022 | $299K | -$16.9M | -$1.53 | -$15M |
| 2021 | $15.6M | $237K | $0.02 | $1.1M |
| 2020 | $6.1M | -$5.8M | -$0.84 | -$4.9M |
Where CLGN ranks in Health care
Latest SEC filings
What CollPlant Biotechnologies Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026
- September 22, 2026
- September 18, 2026
- September 4, 2026
- September 3, 2026
- September 1, 2026
- August 31, 2026
- August 21, 2026Activist stake changed SCHEDULE 13D/A
- August 18, 2026
- August 6, 2026
Insider trades
What the people running CollPlant Biotechnologies Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 3, 2026 | Abelis Bar BertaVP Legal | Received as pay | 201,141 | - |
| September 3, 2026 | Rotem EranDeputy CEO and CFO | Received as pay | 510,372 | - |
Who owns CLGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| The Loewenbaum 1992 Trust13D, may seek influence with 6 related filers | 17.5% | August 21, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 722,813 shares in total, about $3.1M at the last price.
| Holder | Shares |
|---|---|
| Rotem EranDeputy CEO and CFO | 516,372 |
| Abelis Bar BertaVP Legal | 206,441 |
Questions about CLGN
What does CollPlant Biotechnologies Ltd do?
CollPlant Biotechnologies Ltd is registered with the SEC under industry code SIC 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). Its shares trade on NASDAQ under the ticker CLGN.
Is CollPlant Biotechnologies Ltd profitable?
No. In fiscal 2025 it reported a net loss of $11.5M on revenue of $2.4M.
How much revenue does CollPlant Biotechnologies Ltd make?
In fiscal 2025 CollPlant Biotechnologies Ltd reported revenue of $2.4M. That is 360.4% more than a year earlier.
When did CollPlant Biotechnologies Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 26, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 24, 2026.
Similar companies
Compare CLGN with
Follow CLGN
Get an email when CollPlant Biotechnologies Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow CLGN: get an email when it filesWhere the numbers come from
Financial figures are the values CollPlant Biotechnologies Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.